Anuh Pharma Ltd

Key approvals

• Approved investment in manufacturing assets to expand production capacity.
• Loan up to ₹75 crore for asset purchases, subject to terms and approvals.

Board actions

• Board approves investment in manufacturing assets to expand production capacity.
• Board approves loan up to ₹75 crore for asset purchases to expand capacity.
• Terms and approvals to be finalised and disclosed as applicable under SEBI LODR.
• Meeting held 13 Oct 2026; details to be disclosed; website disclosure uploaded.

Anuh Pharma Ltd: Trading window closed from Oct 01, 2026 till 48 hours after declaration of unaudited financial results for the quarter and half-year ended Sep 30, 2026

Filing Status

• Tax dept issued Section 156 demand for AY 2018-19 amount Rs 9,93,206; appeal planned with no financial impact.

Q1 FY27 Highlights

• Revenue 193.81 Cr in Q1 FY27, up 3.93% YoY.
• PAT 11.42 Cr; margin 5.89% vs LY 4.45%.
• EBITDA 19.36 Cr; margin 9.99%.
• Operating Profit 38.15 Cr; margin 19.68%.
• ROCE 19.18%, up 326 bps vs FY26.
• Production 491 MT; +19.46% YoY.

Business Overview

• One of India's largest Macrolides and Anti-TB manufacturers.
• Exports comprised ~46% of FY26 revenue.
• Serves 360 customers in 72+ countries.
• Tarapur plant: 11,400 sq m; 7,800 sq m plot acquired.
• R&D at Mahape: 10,000 sq ft.
• Part of SK Group; ~2,200 employees.
• API manufacturer since 1989.

Infrastructure & Capacity

• Tarapur capacity 2,400 MTPA; 9 API blocks, 2 intermediates.
• Zero Liquid Discharge system; strong compliance.
• USFDA/EU GMP/WHO prequalification at Tarapur.
• DSIR-approved R&D at Mahape.

Future Outlook & Growth

• Growth levers: API volume expansion and regulated-market growth.
• Annual growth target: 15-20%.
• Vonoprazon Fumarate under development.
• Pretomanid under development.
• Edoxaban Tosylate under development.
• Bisoprolol Fumarate under development.

AGM Details

• Date/time: 12 August 2026, 04:00 PM IST; VC/OAVM.
• Meeting concluded at 05:12 PM IST.
• Attendance: 45 members; quorum verified.

Key Resolutions

• Ordinary: Adopt Audited Financial Statements for year ended 31 March 2026.
• Ordinary: Dividend of Rs. 1.50 per equity share proposed.
• Ordinary: Re-appointment of Bipin Nemchand Shah on rotation.
• Ordinary: Re-appointment of Arun Lalchand Todarwal on rotation.
• Ordinary: Ratify remuneration of Cost Auditor Ankit Kishor Chande for FY 2027.
• Special: Revision in remuneration payable to Ritesh B. Shah for 2026-27.
• Special: Revision in remuneration payable to Vivek Shah for 2026-27.
• Special: Adoption of New Memorandum of Association.
• Special: Adoption of New Alterations to Articles of Association.

Voting Status

• Voting results not disclosed; to be declared within two working days.

Director & Auditor Provisions

• Director changes: Re-appointments of Bipin Shah and Arun Todarwal.
• Auditor: Cost Auditor remuneration ratified for FY 2026-27.

Other Approvals

• MOA: Adoption of New Memorandum of Association.
• AOA: Adoption of New Alterations to Articles of Association.

Financials

• Board approved Un-Audited Q1 FY2026 results; revenue from operations ₹19,381.04 lakh; PAT ₹1,142.49 lakh.
• EBITDA ₹1,936.44 lakh; EBITDA margin 9.99%.
• EPS (basic/diluted) ₹1.14; Paid-up capital ₹5,011.20 lakh.
• Total comprehensive income ₹1,139.20 lakh; PAT ₹1,142.49 lakh.

Promoter reclassification withdrawals

• Promoter Group members withdrew requests for reclassification to Public under Reg 31A.
• Remaining promoter group status unchanged; withdrawals effective immediately (06 Aug 2026).

Governance policy

• Adoption of revised Related Party Transactions policy; available on company website.

Withdrawal of reclassification requests

• Three promoter-group shareholders withdrew their requests to reclassify to Public category.
• Withdrawal is effective immediately; they will remain part of the Promoter Group.
• The company previously submitted an application for reclassification on 20 May 2026.
• Exchanges to record withdrawal; no change to promoter status for the signatories.

Financial highlights

• Revenue from operations: Rs 19,381.04 lakh in Q1 FY27; up 3.9% YoY.
• Total revenue for the quarter: Rs 19,688.71 lakh.
• EBITDA: Rs 1,936.44 lakh; EBITDA margin 9.99% (Unaudited).
• PBT: Rs 1,692.81 lakh; PAT after tax: Rs 1,142.49 lakh.
• Basic and diluted EPS: Rs 1.14.
• Total tax expense: Rs 550.32 lakh.
• Other comprehensive income: net of tax Rs -3.29 lakh.
• Bonus issue 1:1 approved Sept 2025; share capital reflected; paid-up capital Rs 5,011.20 lakh.
• Segment: Bulk drug & Chemicals is sole primary reportable segment; no other segments disclosed.
• No subsidiary/associate/joint ventures as of 30 Jun 2026.